Generic Entry into the Regulated Spanish Pharmaceutical Market
- 288 Downloads
This paper empirically analyses entry by generic firms into the strictly regulated Spanish pharmaceutical market. We estimate a fixed effects negative binomial entry model using a panel of 77 active ingredient markets during the period 1999–2005. The results show that generic entry depends positively on revenues, the age of the market, and the number of previous brand-name competitors, and negatively on the number of generic incumbents. We also find that regulation may drive out competition since, contrary to what policy makers might expect, the system of reference pricing restrains generic entry.
KeywordsGeneric entry Pharmaceutical industry Reference pricing
JEL ClassificationI11 L11 L65
Unable to display preview. Download preview PDF.
- Bae J. P. (1997) Drug patent expirations and the speed of generic entry. Health Services Research 32: 187–201Google Scholar
- Borrell J. R., Costas A., Nonell R. (2005) Regulation and competition in the market for pharmaceuticals. In: Puig-Junoy J. (eds) The public financing of pharmaceuticals: An economic approach. Edward Elgar, Cheltenham and Northampton, pp 59–83Google Scholar
- Cameron A.C., Trivedi P.K. (1998) Regression analysis of count data. Econometric society monograph no. 30. Cambridge University Press, CambridgeGoogle Scholar
- Cameron A. C., Trivedi P. K. (2005) Microeconometrics: Methods and applications. Cambridge University Press, CambridgeGoogle Scholar
- Danzon, P. M. & Ketcham, J. D. (2004). Reference pricing of pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand. Forum for Health Economics & Policy, 7 (Frontiers in Health Policy Research), Article 2. Retrieved from http://www.bepress.com/fhep/7/2.
- Ekelund, M. (2001). Generic entry before and after the introduction of reference prices. In M. Ekelund (Ed.), Competition and innovation in the Swedish pharmaceutical market (Chap. 4, pp. 1–17). Dissertation, Stockholm School of Economics.Google Scholar
- Hong S. H., Shepherd M. D., Scoones D., Wan T. T. H. (2005) Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. Journal of Managed Care Pharmacy 11: 746–754Google Scholar
- Hudson J. (2000) Generic take-up in the pharmaceutical market following patent expiry: A multi-country study. International Review of Law and Economics 24: 103–112Google Scholar
- IMS Health. (2006a). Health retail drug monitor: Tracking 13 key global pharma markets. London: IMS Health.Google Scholar
- IMS Health. (2006b). Estudio del impacto de los medicamentos genéricos en el mercado español. Madrid: IMS Health.Google Scholar
- Magazzini L., Pammolli F., Riccaboni M. (2004) Dynamic competition in pharmaceuticals: Patent expiry, generic penetration, and industry structure. European Journal of Health Economics 5: 175–182Google Scholar
- Puig-Junoy J. (2004b) Los medicamentos genéricos pagan el precio de ser referencia. Revista de Administración Sanitaria 2: 35–59Google Scholar
- Segura P. (1997) The peculiar patent and generic situation in Spain. Scrip Magazine 58: 23–25Google Scholar